Mitral Valve Abnormalities Identified by Cardiovascular Magnetic Resonance Represent a Primary Phenotypic Expression of Hypertrophic Cardiomyopathy
Overview
Authors
Affiliations
Background: Whether morphological abnormalities of the mitral valve represent part of the hypertrophic cardiomyopathy (HCM) disease process is unresolved. Therefore, we applied cardiovascular magnetic resonance to characterize mitral valve morphology in a large HCM cohort.
Methods And Results: Cine cardiac magnetic resonance images were obtained in 172 HCM patients (age, 42±18 years; 62% men) and 172 control subjects. In addition, 15 HCM gene-positive/phenotype-negative relatives were studied. Anterior mitral leaflet (AML) and posterior mitral leaflet lengths were greater in HCM patients than in control subjects (26±5 versus 19±5 mm, P<0.001; and 14±4 versus 10±3 mm, P<0.001, respectively), including 59 patients (34%) in whom AML length alone, posterior mitral leaflet length alone, or both were particularly substantial (>2 SDs above controls). Leaflet length was increased compared with controls in virtually all HCM age groups, including young patients 15 to 20 years of age (AML, 26±5 versus 21±4 mm; P=0.0002) and those ≥60 years of age (AML, 26±4 versus 19±2 mm; P<0.001). No relation was evident between mitral leaflet length and LV thickness or mass index (P=0.09 and P=0.16, respectively). A ratio of AML length to LV outflow tract diameter of >2.0 was associated with subaortic obstruction (P=0.001). In addition, AML length in 15 genotype-positive relatives without LV hypertrophy exceeded that of matched control subjects (21±3 versus 18±3 mm; P<0.01).
Conclusions: In HCM, mitral valve leaflets are elongated independently of other disease variables, likely constituting a primary phenotypic expression of this heterogeneous disease, and are an important morphological abnormality responsible for LV outflow obstruction in combination with small outflow tract dimension. These findings suggest a novel role for cardiac magnetic resonance in the assessment of HCM.
Mexican guidelines 2024 for the diagnosis and treatment of hypertrophic cardiomyopathy.
Llamas-Esperon G, Berrios-Barcenas E, Cossio-Aranda J, Guerra-Lopez A, Magana-Serrano J, Iturralde-Torres P Arch Cardiol Mex. 2025; 94(Supl 4):1-75.
PMID: 39928711 PMC: 11824882. DOI: 10.24875/ACM.M25000098.
Sunga C, Yang K, Oyetunji S, Swenson E, Khaira K Reports (MDPI). 2025; 7(4.
PMID: 39822768 PMC: 11737431. DOI: 10.3390/reports7040116.
Shi M, Saleh D, Leya M, Puthumana J, Flaherty J, Choudhury L JACC Case Rep. 2024; 29(22):102653.
PMID: 39691894 PMC: 11646875. DOI: 10.1016/j.jaccas.2024.102653.
Cardiovascular magnetic resonance imaging in mitral valve disease.
Garg P, Pavon A, Penicka M, Uretsky S Eur Heart J. 2024; 46(7):606-619.
PMID: 39565911 PMC: 11825178. DOI: 10.1093/eurheartj/ehae801.
Tondi L, Disabato G, DAndria P, Attanasio A, Guida G, Pieruzzi F Front Cardiovasc Med. 2024; 11:1458705.
PMID: 39411176 PMC: 11475249. DOI: 10.3389/fcvm.2024.1458705.